Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14071895 | 1.00 | TP53 (0.47) | TP53MAPTPPARGPPARACYP2C9 | |
| SCHEMBL30529086 | 1.00 | TP53 (0.47) | TP53MAPTPPARGPPARACYP2C9 | |
| SCHEMBL339515 | 1.00 | TP53 (0.47) | TP53MAPTPPARGPPARACYP2C9 | |
| SCHEMBL14342743 | 0.94 | MAPT (0.47) | TP53MAPTPPARGPPARACYP2C9 | |
| SCHEMBL2523252 | 0.93 | PPARA (0.45) | TP53MAPTPPARGPPARACYP2C9 | |
| SCHEMBL2523255 | 0.93 | PPARA (0.45) | TP53MAPTPPARGPPARACYP2C9 | |
| Potassium Ion SCHEMBL4990138 | 0.93 | MAPT (0.46) | TP53MAPTPPARGPPARACYP2C9 | |
| SCHEMBL2518436 | 0.92 | FFAR1 (0.52) | TP53MAPTPPARGPPARAFFAR1 | |
| SCHEMBL2518434 | 0.92 | FFAR1 (0.52) | TP53MAPTPPARGPPARAFFAR1 | |
| SCHEMBL2519805 | 0.92 | TP53 (0.50) | TP53MAPTPPARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526711-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | claimed |
| US-20160279086-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS INC (US) | 2016-09-29 | — | — | US | claimed |
| US-9394239-B2 | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20140286931-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | claimed |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | claimed |
| US-20100286275-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | US | claimed |
| WO-2010118291-A2 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| EP-1951692-B1 | OXAZOLE AND THIAZOLE PPAR MODULATOR | IRM LLC (BM) | 2010-08-18 | — | — | EP | claimed |
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | claimed |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-07-01 | — | — | US | claimed |
| WO-2007089557-A2 | POLYCYCLIC 1, 2, 3, 4 -TETRAHYDRO- ISOQUINOLINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | claimed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | claimed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | claimed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | claimed |
| EP-1748993-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-02-07 | — | — | EP | claimed |
| WO-2006084176-A2 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2006-08-10 | — | — | WO | claimed |
| WO-2005116000-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2005-12-08 | — | — | WO | claimed |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | BACH ANDREW THOMAS (US) | 2004-12-09 | — | — | US | claimed |
| EP-1448523-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Novartis AG (CH) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043985-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248936-A1 | Heterocyclic compounds and methods of use | PPARG, GPR119, PPARD | TP53 2714/4885MAPT 3732/4885PPARG 1/4885 |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | TP53 2327/4885MAPT 3328/4885PPARG 1/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | TP53 2327/4885MAPT 3328/4885PPARG 1/4885 |
| US-20100286275-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | TP53 4877/4885MAPT 2841/4885PPARG 147/4885 |
| US-20100167988-A1 | ETHOXYPHENYLMETHYL INHIBITORS OF SGLT2 | SLC5A2, SLC5A1, SLC2A4 | TP53 4861/4885MAPT 1024/4885PPARG 143/4885 |
| US-20160279086-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | TP53 4877/4885MAPT 2841/4885PPARG 147/4885 |
| US-20140286931-A1 | BIPHENYL-3-CARBOXYLIC ACID MODULATORS OF BETA-3-ADRENORECEPTOR | ADRB3, ADRB1, ADRA2C | TP53 4877/4885MAPT 2841/4885PPARG 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.